Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, UK
Vinblastine Sulfate 1 mg/ml solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. A clear, colourless sterile solution. |
Each 1 ml contains 1.0 mg of vinblastine sulfate.
Each 10 ml presentation contains 10 mg of vinblastine sulfate.
Excipient with known effect: Each 10 ml vial contains approximately 35 mg (1.5 mmol) sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Vinblastine |
Vinblastine appears to bind to or crystallise critical microtubular proteins of the mitotic spindle, thus preventing their proper polymerisation and causing metaphase arrest. In high concentrations, vinblastine also exerts complex effects on nucleic acid and protein synthesis. |
| List of Excipients |
|---|
|
Sodium chloride |
10 ml, Type I clear conventional glass vial, West Type 1888 rubber closure, aluminium spun cap ring, in packs of 5 vials.
10 ml, Type I clear Onco-Tain vials, West Type 1888 rubber closure, aluminium spun cap ring, in packs of 5 vials.
Not all above presentations and pack sizes may be marketed.
Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, UK
PL 04515/0051
25th September 2003
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
